Losartan potassium/Hydrochlorothiazide
AssetAlso called losartan potassium (+) hydrochlorothiazide, Hyzaar, MK954A, MK0954A
Angiotensin II receptor antagonist combined with a thiazide diuretic to lower blood pressure.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Not known
- 7
- Indications
- 31
- Trials
- 3
- Developers
Approved by the FDA on Apr 28, 1995 (NDA020387). FDA
Indications
74 more
In the full profile
- Target and mechanism1
- Owner and partners3
- Trials31
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.